Sign up Australia
Proactive Investors - Run By Investors For Investors

Orthocell secures European market authorisation for medical device

CelGro device plays a critical role in dental bone and soft tissue regeneration.
a dental clinic
Addressable market of US$600+ million per annum

Orthocell Ltd (ASX:OCC) has received the European regulatory approval (CE Mark) for its CelGro collagen medical device.

CelGro, which is used for a range of dental bone and soft tissue regeneration procedures, can now be marketed and sold within the European Union (EU).

Significantly, the CE mark validates the potential of the entire technology platform by endorsing CelGro’s clinical performance and quality manufacturing.

CelGro is manufactured by Orthocell at its quality controlled Good Manufacturing Practices (GMP) licensed facility in Western Australia.

The company uses its proprietary SMRT tissue engineering process, developed in conjunction with
Professor Minghao Zheng and the University of Western Australia.

CelGro plays a critical role in dental bone and soft tissue regeneration therapy as it offers superior functionality over existing products for improved tissue repair.

CelGro’s dental addressable market is estimated to be worth more than US$600 million per annum, with circa 1.5 million procedures that utilise these types of scaffolds being completed each year.

A key advantage of CelGro over other scaffolds is that it integrates with the soft tissue under repair and also degrades at the same rate as the body heals.

The approval provides a strong foundation for the company to progress additional dental regulatory applications in key markets, such as the U.S., Japan and Australia.





Register here to be notified of future OCC Company articles
View full OCC profile View Profile

Orthocell Ltd Timeline

Newswire
December 05 2016
Newswire
November 16 2015

Related Articles

the word antioxidant
August 15 2017
The heparin test is the firm’s lead product; however the company’s OxiChek device for oxidative stress is also gaining traction
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart
man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use